What do we know about SARS-CoV-2 virus and COVID-19 disease?
More details
Hide details
Chair and Department of Medical Microbiology, University of Medical Sciences, Poznań, Poland
Tomasz M. Karpiński   

Chair and Department of Medical Microbiology, University of Medical Sciences, Poznań, Poland
J Pre Clin Clin Res. 2020;14(2):33–38
Emerging viral diseases are a serious public health problem, especially with such a dynamically changing epidemic situation, in which we are observers and participants. Coronaviruses are present in our lives almost constantly. Currently, the world is struggling with a pandemic caused by the new SARS CoV-2 coronavirus, which is the etiological factor of COVID-19 disease.

The aim of the study is to review scientific reports and systematize current knowledge about SARS-CoV-2 coronavirus and the COVID-19 disease it causes in the face of the ongoing pandemic.

State of knowledge:
The course of SARS-CoV-2 infection is similar to cases caused by coronaviruses of the severe acute respiratory syndrome (SARS-CoV) and the Middle East respiratory syndrome (MERS-CoV). Symptoms vary from mild to viral pneumonia, including fever, difficulty breathing, bilateral infiltrative pneumonia, and multi-organ failure in the most severe cases. COVID-19 disease also leads to complications, such as pulmonary fibrosis, neurological disorders, an increased risk of heart attack, thrombosis, and liver dysfunction. The review presents information about the taxonomy, structure, pathomechanism, clinical symptoms, complications, number of cases, diagnostics, and treatment of COVID-19 disease caused by the SARS-CoV-2 virus.

The SARS-CoV-2 virus has spread quickly around the world, causing a rapidly increasing number of infections and deaths among patients. There is currently no effective vaccine or targeted treatment. The only way to prevent the spread of the virus remains quarantine, the isolation of sick people, and the use of a sanitary regime.

Layton DS, Choudhary A, Bean AGD. Breaking the chain of zoonoses through biosecurity in livestock. Vaccine 2017; 35(44): 5967–5973.
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223): 470–473.
Pyrć K. Ludzkie koronawirusy. Postępy Nauk Med. 2015; 28(4B): 48–54.
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020; 382(10): 929–936.
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020; 55(3): 105924.
WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19. 11 March 2020.
Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020.
Ji W, Wang W, Zhao X, Zai J, Li X. Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human. J Med Virol. 2020; 92: 433–440.
Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new coronavirus epidemic: Evidence for virus evolution. J Med Virol. 2020; 92(4): 455–459.
Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1): 221–236.
Hui DS, Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health – The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020; 91: 264–266.
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270–273.
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798): 265–269.
Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020; 27(3): 325–328.
CDC. How coronavirus spreads. 2020.
Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020; 92(4): 418–423.
Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY. Coronaviruses-drug discovery and therapeutic options. Nat Rev Drug Discov. 2016; 15: 327–347.
NCPERE Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) – China, 2020. China CDC Weekly. 2020; 2(8): 1–10.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727–733.
Hulswit RJ, de Haan CA, Bosch BJ. Coronavirus spike protein and tropism changes. Adv Virus Res. 2016; 96: 29–57.
Luo W, Yu H, Gou J, Li X, Sun Y, Li J, Liu L. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints. 2020:2020020407.
Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003; 361(9371): 1773–8.
Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46(4): 586–590.
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483): 1260–1263.
Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020.
Lisa E, Gralinski LE, Menachery VD. Return of the coronavirus: 2019- nCoV. Viruses. 2020; 12(2): 135.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020. pii: S2213-2600(20)30079-5. https://doi. org/10.1016/S2213-2600/20/30079-5.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 20:c 30183–30185.
Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z, et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020. pii: ciaa198.
Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020.
Wei M,Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel coronavirus infection in hospitalized infants under 1 year of age in China. JAMA. 2020. https://
WHO. Q&A: Similarities and differences – COVID-19 and influenza. 2020.
Yadav M. Understanding the epidemiology of COVID-19. Eur J Biol Res. 2020; 10: 105–117.
ECDC. ECDC Situation update worldwide. 2020. https://www.ecdc.
CDC. Information for Laboratories. 2020. coronavirus/2019-nCoV/lab/index.html.
CDC. Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19). 2020. specimens.html.
CDC. Types of specimens. 2020. laboratory-support.
WHO. Novel-coronavirus-2019. 2020. emergencies/diseases/novel-coronavirus-2019/technical-guidance/ laboratory-guidance.
Vashist SK. In vitro diagnostic assays for COVID-19: recent advances and emerging trends. Diagnostics 2020;10:202. diagnostics10040202.
Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections – the state of the art. Emerg Microbes Infect. 2020; 9(1): 747–756.
Zhengtu L, Yongxiang Y, Xiaomei L, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020: 1–7.
Cinquanta L, Ethel Fontana D, Bizzaro N, Cinquanta L, Ethel Fontana D, Bizzaro N. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? Autoimmun Highlights. 2017; 8:9.
Jin Y, Wang M, Zuo Z, Fan C, Ye F, Cai Z, et al. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. Int J Infect Dis. 2020; 94: 49–52.
Johns Hopkins Center for Health. 2020. Serology testing for COVID-19. https://www. COVID-19-fact-sheets/200228-Serology-testingCOVID.pdf.
Zhang W, Du R, Li B, Zheng X-S, Yang X-L, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microb. 2020; 9: 386–389. https://
Jia X, Zhang P, Tian Y, Wang J, Zeng H, Wang J, et al. Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection. medRxiv. 2020, https://doi:10.1101/2020.02.28....
Zhang J, Liu J, Li N, Liu Y, Ye R, Qin X, et al. Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing. medRxiv. 2020,
Desjardins M, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic testing for severe acute respiratory syndrome– related coronavirus-2. Ann Intern Med. 2020. M20-1301.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269–271. https://doi. org/10.1038/s41422-020-0282-0.
Cortagiani A, Ingoglia G, Ippolito M, Giarrantano A, Einav S. A sytematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020.pii: S0883-9441(20)30390-7.
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020. pii: jbc.AC120.013056. AC120.013056.
de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020. pii: jbc.AC120.013056.
Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020; 10.1002/ddr.21656. https://doi. org/10.1002/ddr.21656.
Shen C, Wang Z, Zhao F, Yang Y, Li J, Juan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020; 323(16): 1582–1589.
Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. PNAS 2020; 117: 9490–9496.
Giovanetti M, Benvenuto D, Angeletti S, Ciccozzi M. The first two cases of 2019-nCoV in Italy: Where they come from? J Med Virol. 2020; 92(5): 518–521.
Phase 1 open-label study to evaluate the safety tolerability and immunogenicity of INO-4800, a prophylactic vaccine against SARSCoV- 2, administered intradermally followed by electroporation in healthy volunteers. NCT04 336 410. 2020.
Mahase E. Covid-19: what do we know so far about a vaccine? BMJ. 2020; 369: m1679.
A phase I clinical trial for recombinant novel coronavirus (2019-CoV) vaccine adenoviral. ChiCTR2 000 030 906. 2020. showprojen.aspx?proj=51154.
A phase I/II study to determine efficacy safety and immunogenicity of the candidate coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers. NCT04 324 606. 2020. https://
Gao Q, Bao L, Mao H, Wang L, Xu K, YangM, et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020: eabc1932.
Van Doremalen N, Bushmaker T, Morris D, Holbrook M, Gamble A, Williamson B, et al. Aerosol and surface stability of HCoV-19 (SARSCoV-2) compared to SARS-CoV-1. New Engl J Med. 2020. doi: 10.1056/ NEJMc2004973.
Duan SM, Zhao XS, Wen RF, Huang JJ, Pi GH, Zhang SX, et al. Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. Biomed Environ Sci. 2003; 16(3): 246–55.
Darnell ME, Subbarao K, Feinstone SM, Taylor DR. Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARSCoV. J Virol Methods. 2004; 121(1): 85–91. jviromet.2004.06.006.
WHO. Water, sanitation, hygiene and waste management for COVID-19. 19 March 2020.
Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020; 104(3): 246–251.
Sheng G, Chen P, Wei Y, Yue H, Chu J, Zhao J, et al. Viral infection increases the risk of idiopathic pulmonary fibrosis: a meta-analysis. Chest. 2019. pii: S0012-3692(19)34200-X. chest.2019.10.032.
Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, et al. SARSassociated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004; 39(2): 302–10. hep.20111.
Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol. 2020; 70(9): 311–22. https://doi:10.33588rn.7009.20....
Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020; S0735–6757(20): 30277–1. https://doi:10.1016/j.ajem.202....